VivoSeq
Other

Autonomous Cortisol Secretion

1

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Autonomous Cortisol Secretion is an early-stage landscape with 1 program across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

19/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Ketoconazole

Wim Janssens

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Recruiting·JJohns Hopkins University·Phase 4·NCT07247058·10 enrolled
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Not yet recruiting·UUniversity of Texas Southwestern Medical Center·N/A·NCT07361874·75 enrolled
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
Recruiting·LLaikο General Hospital, Athens·Phase 4·NCT07268222·150 enrolled
Ketoconazole Effects on Cortisol Circadian Rhythm in Mild Autonomous Cortisol Secretion: A Pilot Study
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT07649317·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)